Headache News and Research

Latest Headache News and Research

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2011.

5 May 2011

Headache disorders prevalent but under-treated and cause financial burden, WHO report says

Approximately half to three quarters of adults ages 18 to 65 experienced headache last year, making headache disorders one of the most prevalent but under-treated health problems in the world, according to a report released Tuesday by the WHO, Xinhua reports.

5 May 2011

South Australian man succumbs to Murray Valley Encephalitis

A 27-year-old South Australian Riverland man has succumbed to Murray Valley Encephalitis (MVE) – a viral disease that is carried by mosquitoes. According to SA Health's chief medical officer Paddy Phillips, the man had been receiving hospital care for MVE since March.

3 May 2011

Affinium announces AFN-1252 Phase I study results in staphylococcal infections

Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation.

3 May 2011

Scientists discover new gene underlying angle-closure glaucoma

Jackson Laboratory researchers and their collaborators have reported their discovery of a gene implicated in an acute and severe form of glaucoma known as angle-closure glaucoma.

3 May 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Vertex Pharmaceuticals Incorporated announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.

29 Apr 2011

More women using ‘morning after’ pill

Figures have revealed that the rate of women using emergency contraception in 2006-08 more than doubled, compared with the rate in the previous four to six years, before the pills were approved for use without a prescription. This comes from a study from the Guttmacher Institute.

29 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

Tips for parents to identify concussions in young athletes

A recent study found that many parents feel they lack the knowledge to adequately detect symptoms of head injuries in their children. Yet keeping young athletes off the field until they've fully healed from a concussion is key to preventing serious and potentially fatal complications.

27 Apr 2011

Common painkillers decrease effectiveness of antidepressants: Study

According to a latest study, antidepressants like Prozac and Aspirin do not mix. Researchers found that painkillers such as aspirin and ibuprofen appear to decrease the effectiveness of a popular class of antidepressants that includes Prozac, Paxil, Lexapro and Zoloft and Celexa.

26 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

GSK receives FDA approval for Lamictal XR to treat partial seizures

GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.

26 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Noninvasive Masimo carboxyhemoglobin can effectively screen ED patients for CO poisoning

Masimo announced today that a new study published in this month's issue of the peer-reviewed journal, Annals of Emergency Medicine, demonstrates that noninvasive Masimo carboxyhemoglobin measurements provide an "effective means for screening at-risk populations for CO poisoning" with "acceptable bias and precision" compared to invasive blood gas analysis.

25 Apr 2011

Headache News and Research

Latest Headache News and Research

Acorda reports $0.7 million GAAP net loss for first quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

Headache disorders prevalent but under-treated and cause financial burden, WHO report says

South Australian man succumbs to Murray Valley Encephalitis

Affinium announces AFN-1252 Phase I study results in staphylococcal infections

Scientists discover new gene underlying angle-closure glaucoma

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

Boehringer Ingelheim, Eli Lilly receive FDA approval for Tradjenta to treat type 2 diabetes

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

More women using ‘morning after’ pill

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Tips for parents to identify concussions in young athletes

Common painkillers decrease effectiveness of antidepressants: Study

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

GSK receives FDA approval for Lamictal XR to treat partial seizures

Nausea and vomiting are most feared of all chemotherapy-related side effects

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Noninvasive Masimo carboxyhemoglobin can effectively screen ED patients for CO poisoning

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in